The AIR042A COVID-19 Status Report has been updated. The report will now identify individuals who have started but not completed their primary COVID-19 vaccination course.
See user guide on how to access the AIR042A report on the AIR site via HPOS.
NSW Health exemption form
From 25 February 2022, the NSW COVID-19 medical contraindication form will no longer be an acceptable form of evidence for exemption from the requirement for mandatory vaccination under the various public health orders. The AIR IM011 form immunisation medical exemption is now the only valid exemption form.
Boosters required for up-to-date status
ATAGI advises that all individuals aged 16 years and over are recommended to receive a COVID-19 vaccine booster dose to maintain an “up-to-date” status. This booster dose is now recommended from 3 months after the last primary dose. This is called the ‘due date’.
Booster – updated advice
ATAGI have updated their recommendations on the use of booster doses of COVID-19 vaccine. What’s changed:
Novavax can be used as a booster in people 18+ years if all other COVID-19 vaccines are unsuitable.
AstraZeneca is no longer recommended as a booster dose for people who received AstraZeneca for the first and second dose. AstraZeneca is now only recommended when mRNA vaccines are contraindicated or if patientdeclinean mRNA vaccine.
Pfizer or Moderna is preferred as booster for people 18+ years.
Only Pfizer should be used as a booster for people aged 16 – 17 years.
All primary care vaccination providers currently registered with CVAS (who are also currently on the VCF) will have already received a registration email with details on how to register to use VCF Connect. The email will have come from CV19.Products@health.gov.au. If you have not received this email, phone 1800 316 375. For more information, see VFC Connect FAQs.
The “Tree of community informed strategies to increase childhood vaccination rates” resource presents practical strategies for health services to improve childhood vaccination rates in communities that may generally support vaccination, but experience socio-economic disadvantage and access barriers to immunisation services. The ‘tree’ may also be used by communities to start a conversation about what makes it difficult or easy to get children vaccinated on time in their community, and advocate for changes.
Updated COVID-19 vaccination resources
Temporary medical exemptions
Updated ATAGI expanded guidance on COVID-19 vaccine temporary medical exemptions – changes include:
Rapid antigen tests (that where possible have been reported to the relevant State or Territory reporting system) are now considered acceptable proof of infection for the purposes of a temporary medical exemption to delay vaccination.
The time frame for temporary deferral of vaccination following SARS-CoV-2 infection has been updated from 6 months to 4 months.
The guidance supports the AIR IM011 form immunisation medical exemption.
Palliative care and/or end-of-life care
Updated COVID-19 vaccination decision guide for people receiving palliative care and/or end-of-life care – changes include:
Information on Nuvaxovid (Novavax) COVID-19 vaccination has been added
Information on COVID-19 vaccine boosters has been updated
Information on Spikevax COVID-19 vaccine (Moderna) in children aged 6-11 years has been added
People with immunocompromise
Updated ATAGI provider guide to COVID-19 vaccination of people with immunocompromise – changes include:
people aged 16 years and older who have received a 3-dose primary course due to severe immunocompromise are recommended to receive a booster (i.e. 4th) dose 3 months or more after their 3rd dose
information on Nuvaxovid COVID-19 Vaccine (Novavax) has been included
people aged 6 to 11 years can now receive Spikevax (Moderna) (half the adult dose)
This guide contains information about the COVID-19 vaccines Comirnaty (Pfizer), Spikevax (Moderna), Vaxzevria (AstraZeneca) and Nuvaxovid (Novavax)
COVID-19 live stream update for GPs
Join the latest COVID-19 vaccine live stream update for GPs. The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…